Publications
CAR T Cells
G-Rex®24 Well Plate
Publication Date: April 9, 2024
A single activation combined with a 3-day seed train gave higher yield and better-quality CAR-T cells than two activations with a 7-day seed train. The team used a design-of-experiments approach in G-Rex® 24-well plates, varying activations, seed train time, seeding density and IL-2 from 30 to 100 IU/mL. Conditions activated once reached a mean cell fold of 28.7 versus 8.6 after seven days, and 48.5% versus 77.5% of cells co-expressed PD1 and LAG3. In flasks with three donors, cell fold was 93.8 versus 16.9. In the Ambr 250 High Throughput bioreactor, the optimised process reached 7.1e6 versus 4.6e6 cells/mL, with only 8% of cells CD3+PD1+LAG3+. IL-2 concentration did not significantly af…
Publications
TCR T Cells
G-Rex®6M Well Plate
Publication Date: April 4, 2024
A T-cell receptor that recognizes the tumor antigen mesothelin without needing HLA presentation was isolated from a naive human TCR phage display library and shown to work in primary T cells. The receptor bound mesothelin with a KD of 1.1 μM, activated Jurkat cells and primary T cells against mesothelin-positive lines and patient-derived xenograft cells, and worked in both CD4 and CD8 cells. Mutating CDR1 positions produced variants with roughly tenfold higher and lower affinity. Unlike a TCR fusion construct, it was not inhibited by up to 40 μM soluble mesothelin. In Capan-2 xenografted NSG mice, doses of 1 × 10^6 T cells or more caused full tumor regression, while the comparator constru…
Publications
CAR T Cells
Publication Date: March 19, 2024
A CD33-targeted chimeric immunoreceptor split into separate antigen-binding and signaling chains, called DARIC33, triggered T cell killing of acute myeloid leukemia cells only when rapamycin was present to join the two chains. Half-maximal cytokine release needed only 15.8 to 74.2 pM rapamycin. In NSG mice bearing MOLM14 leukemia, DARIC33 T cells followed by 0.1 mg/kg rapamycin three times weekly delayed tumor growth and significantly extended survival, whereas the same cells without rapamycin did not. Stopping rapamycin let tumors relapse in four of five mice, and restarting it on day 28 restored control in four of five. A donor-matched clinical-scale product suppressed Raji.CD33 tumors…
Publications
CAR T Cells
G-Rex®6M Well Plate
Publication Date: March 14, 2024
Low-dose targeted radionuclide therapy delivered through tumor-infiltrating CAR T cells caused rapid regression of gastric tumors in mice that responded only modestly to CAR T cells alone. The ICAM-1 and EpCAM CARs were co-expressed with SSTR2, so CAR T cells could be tracked by 18F-NOTA-Octreotide PET and could capture 177Lu-DOTATATE. In the Hs 746T model, 7.4 MBq given on day 28, once PET showed substantial CAR T accumulation, delivered 2.55 ± 1.17 Gy to the tumor and 0.75 Gy to the kidneys; 5 of 6 treated mice had complete tumor regression within 3–4 weeks and survival improved. Serum IFN-γ and perforin rose after treatment. In relapsed SNU-638 tumors, 37 MBq delivered 6.02 ± 1.35 Gy a…
Publications
CAR T Cells
G-Rex®100M, G-Rex®500M
Publication Date: March 12, 2024
Under identical media, stimulation, culture length and donor cells, four CAR-T expansion platforms produced cells in different differentiation states. FGFR4 CAR-T cells from four healthy donors were grown for 14 days in bags, a 5 L G-Rex®, a Xuri W25 or a CliniMACS Prodigy. Bags gave the highest mean fold expansion (481.2), the Prodigy the lowest output (4.2 × 10^9 cells), and the G-Rex® 9.5 × 10^9 cells with less variability than the Xuri. On day 14, 46.6% of Prodigy cells were Tn/scm-like, against 15.6% in bags and 12.6% in G-Rex®. Dissolved oxygen in the Prodigy fell to 97 mmHg; culturing bag and G-Rex® cells at 1% O2 for 9 days raised Tn/scm-like cells to 78.7% and 62.7%, but reduced…
Publications
CAR T Cells, γδ T
Publication Date: March 12, 2024
Growing CD19-targeted CAR-Vδ2 T cells in medium supplemented with human platelet lysate (HPL) rather than fetal bovine serum (FBS) improved their anti-tumor activity and persistence in mice. Donor PBMCs were stimulated with zoledronate and IL-2, γδ T cells were transduced with CD19 CARs carrying CD28, 4-1BB or CD27 costimulatory domains, and cultures were expanded for 14 more days. HPL gave higher expansion with comparable CAR expression, cytotoxicity and cytokine release in vitro. In NSG mice bearing NALM6 leukemia, HPL-expanded cells controlled tumors better and prolonged survival, with the 4-1BB CAR performing best. RNA sequencing found 4,561 differentially expressed genes; FBS-grown c…
Publications
NK Cells
Publication Date: March 5, 2024
Expanding natural killer cells and strengthening their function are the main routes to making NK cells a practical adoptive cell therapy. This review compares cytokine-based and feeder-cell-based expansion: IL-2 with PBMC gave a 193-fold expansion in 21 days, while K562 feeder cells engineered to express membrane-bound IL-21 produced a 47,967-fold expansion by day 21 and maintained growth without senescence for up to 6 weeks. It also covers culture materials, telomere length, and cytotoxicity. Memory-like NK cells, CAR-NK cells and tumor-infiltrating NK cells are described as ways to improve persistence and tumor targeting, with early clinical trials reporting safety and responses, includ…
Publications
NK Cells
G-Rex®24 Well Plate
Publication Date: March 1, 2024
Induced pluripotent stem cell-derived NK cells engineered with a synNotch circuit that senses CD155 through a TIGIT ligand and releases an anti-CD73 scFv showed strong activity against glioblastoma in preclinical models. Engineered cells expanded at rates similar to unmodified cells and reached more than 80% NK purity after two weeks of expansion. In vitro, they lysed CD155+CD73+ GBM43 cells at significantly higher levels than unmodified iNK cells. In NSG mice carrying intracranial GBM43-luciferase tumors, three weekly intracranial doses of 2 × 10^6 engineered cells sharply reduced tumor growth and improved survival compared with PBS or unmodified cells. In immunocompetent mice, combined…
Publications
CAR T Cells, CD34 Cells
Publication Date: February 27, 2024
In humanized BLT mice and SHIV-infected pigtail macaques, CD4-based anti-HIV CAR cells generated from modified hematopoietic stem/progenitor cells expanded, suppressed plasma viremia and reached more tissues than autologous peripheral CAR T cells, which declined within weeks of infusion. Mice received 10 million mock or CAR-transduced T cells per infusion; culturing those cells in IL-7 and IL-15 instead of IL-2 modestly improved persistence and maintained central memory and CD27 expression, while intraperitoneal IL-7 and IL-15 lowered immune activation and exhaustion markers without improving expansion or viral control. Second-generation CD4CAR41BB cells lowered spleen viral RNA relative…
Publications
CTL Cells, Other, VST Cells
Publication Date: February 18, 2024
Greece's three public umbilical cord blood (UCB) banks pursue financial sustainability by prioritizing HLA-diverse donations and by repurposing units unsuitable for transplantation, which make up about 90% of donations. Over 10 years, 1103 unrelated-donor allogeneic transplants were performed in Greece, but only 236 used Greek donors, reflecting national HLA heterogeneity. Among 2869 banked units screened in the HAPLO-iPS COST Action, 3 were homozygous for one three-locus HLA haplotype, estimated to cover 5.68% of the Greek population; the top 10 and 100 haplolines would cover 23.07% and 51.11%. Non-transplantable units have supplied dendritic cells to generate bivalent WT1- and PRAME-spe…
Publications
CAR T Cells
G-Rex®10M
Publication Date: February 13, 2024
A membrane-proximal CD22 epitope, rather than antibody affinity, determined which llama single-domain antibody CAR-T cells killed lymphoma in vivo. Immunizing a llama with the CD22 extracellular domain and two phage-panning strategies yielded 27 unique single-domain antibodies, 20 of which bound CD22 with affinities from 0.03 to 250 nM across 7 noncompetitive epitope bins. Screening 22 CAR constructs in Jurkat cells showed activation unrelated to on-rate, off-rate or affinity, while switching the CD28 transmembrane domain for CD8 raised CAR expression and persistence. In blinded NSG xenografts, 2.5 × 10^6 1ug36 CAR-T cells extended survival, and 12.5 × 10^6 cells eradicated Ramos lymphoma…
Publications
TIL Cells
G-Rex®10, G-Rex®100M
Publication Date: February 2, 2024
Tumor-infiltrating lymphocytes (TIL) expanded with IL-2 plus agonistic anti-CD3 and anti-4-1BB stimulation were manufactured for every enrolled patient in a phase II trial in refractory colorectal, pancreatic and ovarian cancer, but produced no objective responses. After lymphodepleting chemotherapy, 16 patients (8 colorectal, 5 pancreatic, 3 ovarian) received a median of 7.6 × 10^10 TIL followed by high-dose IL-2. Ten patients had stable disease, a disease control rate of 62.5%, and one pancreatic cancer patient remained stable for 17 months. Median progression-free and overall survival were 2.53 and 18.86 months. Toxicities were mainly expected cytopenias, including grade 4 platelet cou…
No manuscripts match your filters.